Skip to content

Alumis Inc. ALMS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$1.7M
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$327K+61.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$1.07B+506,582%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$713K-92.3%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$120K-7.0%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$23.37M+96.1%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s stock issuance proceeds?
Alumis Inc. (ALMS) reported stock issuance proceeds of $323.8M in Q1 2026.
How has Alumis Inc.'s stock issuance proceeds changed year-over-year?
Alumis Inc.'s stock issuance proceeds increased by 264764.6% year-over-year, from $122.25K to $323.8M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.